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Abstract
Infections with the picornavirus, human rhinovirus (HRV), are a major cause of wheezing illnesses and asthma exacerbations.
In developing a murine model of picornaviral airway infection, we noted the absence of murine rhinoviruses and that mice
are not natural hosts for HRV. The picornavirus, mengovirus, induces lethal systemic infections in its natural murine hosts,
but small genetic differences can profoundly affect picornaviral tropism and virulence. We demonstrate that inhalation of a
genetically attenuated mengovirus, vMC0, induces lower respiratory tract infections in mice. After intranasal vMC0
inoculation, lung viral titers increased, peaking at 24 h postinoculation with viral shedding persisting for 5 days, whereas
HRV-A01a lung viral titers decreased and were undetectable 24 h after intranasal inoculation. Inhalation of vMC0, but not
vehicle or UV-inactivated vMC0, induced an acute respiratory illness, with body weight loss and lower airway inflammation,
characterized by increased numbers of airway neutrophils and lymphocytes and elevated pulmonary expression of
neutrophil chemoattractant CXCR2 ligands (CXCL1, CXCL2, CXCL5) and interleukin-17A. Mice inoculated with vMC0,
compared with those inoculated with vehicle or UV-inactivated vMC0, exhibited increased pulmonary expression of
interferon (IFN-a, IFN-b, IFN-l), viral RNA sensors [toll-like receptor (TLR)3, TLR7, nucleotide-binding oligomerization domain
containing 2 (NOD2)], and chemokines associated with HRV infection in humans (CXCL10, CCL2). Inhalation of vMC0, but not
vehicle or UV-inactivated vMC0, was accompanied by increased airway fluid myeloperoxidase levels, an indicator of
neutrophil activation, increased MUC5B gene expression, and lung edema, a sign of infection-related lung injury. Consistent
with experimental HRV inoculations of nonallergic, nonasthmatic human subjects, there were no effects on airway
hyperresponsiveness after inhalation of vMC0 by healthy mice. This novel murine model of picornaviral airway infection and
inflammation should be useful for defining mechanisms of HRV pathogenesis in humans.
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Introduction
Infections with the picornavirus, human rhinovirus (HRV), are
the most frequent cause of the common cold. However, HRV
infections, which usually cause self-limiting upper respiratory tract
illnesses, are also the leading cause of virus-induced asthma
exacerbations [1], and HRV wheezing illnesses in the first few
years of life are associated with increased risk for the development
of childhood asthma [2–4]. The mechanisms by which a common
cold virus can induce asthma exacerbations and contribute to the
development of persistent lower airway sequelae in susceptible
children remain to be elucidated [5,6].
There is considerable evidence that HRV can infect the lower
respiratory tract [7–14] and that HRV infection stimulates the
production of proinflammatory chemokines and cytokines by
lower airway epithelial cells [15]. Neutrophils are the main first-
line inflammatory cells recruited to the airways during HRV
infections [16–18], and this neutrophilic inflammatory response
has been associated with asthma symptoms and airway dysfunc-
tion [19–22]. However, the relationship between neutrophilic
airway inflammation and HRV-induced airway disease is still
largely undefined. The eventual outcome of HRV infection, a
relatively uneventful upper respiratory tract illness versus a more
severe lower respiratory tract illness, might be related to the
balance between detrimental and beneficial effects of the
neutrophilic inflammatory response in the airways, which might
be influenced by host, viral, developmental, and environmental
factors. The development of useful small animal models of
picornavirus-induced neutrophilic airway inflammation could
facilitate mechanistic studies to address these issues.
There are no known murine rhinoviruses, which has signifi-
cantly hampered the investigation of the mechanisms governing
the inflammatory responses to HRV infection and the subsequent
development of airway sequelae. Experimental models using either
minor receptor group HRV in wild-type mice or major receptor
group HRV in mice that are transgenic for human intercellular
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group HRV, have been developed recently [23–28]. A limitation
of these useful models is that HRV titers exhibit a steep decline
after inoculation of normal mice [23–26]. The development of
rodent models in which picornavirus replication persists for several
days in the airways of unmanipulated hosts, as in experimental and
clinical HRV infections, could facilitate investigation of the
relationships between viral replication and the development of
airway inflammation and dysfunction. For this reason, we have
explored the use of a murine picornavirus, which replicates
efficiently in its natural hosts, to model picornavirus-induced
respiratory infections.
Mice are the natural hosts for mengovirus, a picornavirus whose
wild-type form causes infections that are more similar to systemic
poliovirus infections than to HRV-induced airway infections [29].
The mengovirus genome has a poly(C) tract in the distal region of
its 59 untranslated region, which has been shown to be an
important virulence determinant that inhibits host type I
interferon (IFN) responses [30–34]. Investigation of a mengovirus
mutant, vMC0, in which the poly(C) tract had been deleted
showed that vMC0 induces robust type I IFN responses and that
vMC0 inoculation by intracerebral or intraperitoneal routes results
in self-limited infections rather than the often lethal, systemic
infections induced by wild-type mengovirus [30–34]. Wild-type
mengovirus efficiently replicates in both epithelial and macro-
phage lineage cells; however, vMC0, like HRV, replicates well in
epithelial cells but poorly in macrophage lineage cells [34,35].
These similarities between vMC0 and HRV led us to hypothesize
that vMC0 could produce a respiratory tract infection in rodents
akin to HRV infections in humans. Using rats, were able to
demonstrate that inoculation of vMC0 by an inhalation route
could induce infection of the lower airways and neutrophilic
airway inflammation [36]. An effective HRV infection model has
not been established in rats. Therefore, vMC0 should be useful for
investigating picornavirus-induced airway infections in rats, and
studies to explore the effects of vMC0 infection in an established
rat model of allergic airway inflammation are underway.
However, the much wider range of mutant strains and genetic
tools available in the mouse also made it highly desirable to
develop a robust murine model of vMC0-induced airway infection.
In this paper, we demonstrate that inhalation of the genetically
attenuated mengovirus, vMC0, induces an acute lower respiratory
tract illness in mice, which is characterized by replication and
persistent shedding of virus and neutrophilic airway inflammation
with evidence of neutrophil activation and lung injury. This novel
murine model of picornavirus-induced lower respiratory tract
infection and inflammation should be useful for investigating
mechanisms of HRV pathogenesis in humans.
Results
Viral replication and persistent viral shedding in the
lungs after inhalation of attenuated mengovirus, vMC0
After an intranasal inoculation of 10
6 plaque-forming units
(PFU) of attenuated mengovirus, vMC0, a median of 5.4610
3 PFU
were detected in whole lung homogenates from mice at 0.1 h
postinoculation, with viral titers remaining relatively stable at 1
Figure 1. Differences between attenuated mengovirus and
HRV in the kinetics of lung viral titers. Mice received intranasal
inoculations of 10
6 PFU of attenuated mengovirus, vMC0 [A (n=7 mice
per group), B (n=6 mice per group)], or 5610
6 PFU of HRV-A01a (C;
n=4 mice per group). Lungs were harvested at the indicated times, and
viral titers in lung homogenates were determined by plaque assays.
Data are the total amount of virus present in the lung homogenates
(virus concentrations were multiplied by lung homogenate volumes).
No virus was detected in lungs from vehicle-inoculated mice. Data are
presented as box plots. For one HRV-A01a-inoculated mouse at 3 h
postinoculation, a value of 1 PFU was assigned for graphing purposes
because virus was undetectable. ND, not detectable.
doi:10.1371/journal.pone.0032061.g001
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there was a marked increase in viral titers to median levels of
5.3610
5 and 6.9610
6 PFU, respectively, which is indicative of
substantial viral replication in the lung (Fig. 1A). Infectious vMC0
continued to be shed in the lungs for at least 5 days postinoculation
(Fig. 1B). In contrast, after intranasal inoculation of 5610
6 PFU of
HRV-A01a, a minor receptor group HRV, a median of 3.4610
3
PFU were detected in whole lung homogenates at 0.1 h
postinoculation, and viral titers declined until they were
undetectable at 24 h postinoculation (Fig. 1C). No virus was
detected in vehicle-inoculated mice. These data show that
inhalation of vMC0, compared with that of HRV-A01a, resulted
in more robust viral replication and greater persistence of viral
shedding in the lungs.
Type I and III IFN production in the lungs after inhalation
of vMC0
The induction of type I and III IFN is a key component of the
host response to HRV infection [37–39] and an indicator of viral
replication. Intranasal inoculation with vMC0, but not UV-
inactivated vMC0, resulted in significant increases in bronchoal-
veolar lavage (BAL) fluid levels of the type I IFNs, IFN-a and IFN-
b, and type III IFN, IFN-l, compared with those in vehicle-
inoculated mice on days 1 and 2 postinoculation (Fig. 2). Thus,
vMC0-induced IFN production required replication competent
virus.
Pulmonary expression of viral RNA sensors after
inhalation of vMC0
Pattern recognition receptors, toll-like receptor (TLR)3 and
TLR7, have been implicated as viral RNA sensors in the host
response to HRV infection [40,41]. NOD2 (nucleotide-binding
oligomerization domain containing 2) is a pattern recognition
receptor that detects bacterial peptidoglycan, but which has been
shown recently to also function as a viral RNA sensor [42].
Inhalation of vMC0, but not UV-inactivated vMC0, resulted in
significant increases in TLR3, TLR7, and NOD2 mRNA levels
in the lungs on day 1 postinoculation compared with mRNA levels
in vehicle-inoculated mice, indicating the stimulation of viral RNA
sensor pathways (Fig. 3A–C). Pretreatment of mice with an anti-
neutrophil monoclonal antibody (mAb) did not result in reduced
pulmonary expression of TLR3, TLR7, or NOD2 mRNA in
vMC0-inoculated mice on day 1 postinoculation in comparison
with vMC0-inoculated mice that had been pretreated with a
control mAb (Fig. 3D–F); indeed, a significant increase in TLR7
mRNA expression was observed in the anti-neutrophil mAb-
treated group (Fig. 3E). Thus, the observed increases in TLR3,
TLR7, and NOD2 mRNA levels after inhalation of vMC0 were
apparently due, at least in part, to increased expression in resident
lung cells rather than being solely due to the recruitment of
neutrophils that might express these receptors. In vehicle-
inoculated mice, pretreatment with the anti-neutrophil mAb
resulted in a significant decrease in TLR3 mRNA levels compared
with pretreatment with the control mAb (Fig. 3D).
Body weight loss after inhalation of vMC0
Body weight reduction is a sensitive measure of viral respiratory
illness in rodents [43]. Intranasal inoculation of vMC0 led to a
significant loss of body weight on days 2 and 3 postinoculation
compared with inoculation with either vehicle or UV-inactivated
vMC0, which showed that the mice were experiencing a viral
illness (Fig. 4). Mice inoculated with vMC0 also exhibited
significant body weight loss compared with those inoculated with
vehicle, but not UV-inactivated vMC0, on day 1 postinoculation
and those inoculated with UV-inactivated vMC0, but not vehicle,
on day 5 postinoculation (Fig. 4). Inoculation with UV-inactivated
Figure 2. Induction of type I and III IFN expression in response
to inhalation of attenuated mengovirus. Mice received intranasal
inoculations of 10
6 PFU of attenuated mengovirus, vMC0, an equivalent
amount of UV-inactivated vMC0, or vehicle (n=6 mice per group).
Levels of (A) IFN-a, (B) IFN-b, and (C) IFN-l protein in BAL fluid on days 1
and 2 postinoculation were determined by ELISA. Data are the total
amount of IFN recovered (ELISA values were multiplied by the BAL fluid
volume). IFN-l protein levels below the limit of detection (dotted line)
were assigned a value of 5 pg for graphing purposes. Data are
presented as box plots. Veh, vehicle; ND, not detectable. * P#0.01
(vMC0 vs. vehicle or UV-inactivated vMC0).
doi:10.1371/journal.pone.0032061.g002
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inoculation with vehicle, indicating a requirement for replication-
competent virus for the development of illness (Fig. 4).
Inflammation in the lower airways after inhalation
of vMC0
Intranasal inoculation of vMC0 induced the recruitment of
inflammatory cells into the lower airways. Total numbers of BAL
cells were significantly elevated on days 1, 3, and 5 postinoculation
in mice inoculated with vMC0 compared with those inoculated
with UV-inactivated vMC0 or vehicle (Fig. 5A). Neutrophils
(Fig. 5B) and lymphocytes (Fig. 5C) were the most prominent cell
types recruited to the lower airways; numbers of BAL neutrophils
and lymphocytes were significantly elevated on days 1, 2, and 3
and days 1, 2, 3, and 5 postinoculation, respectively, in vMC0-
inoculated mice as compared with mice inoculated with vehicle or
UV-inactivated vMC0. BAL macrophages were only significantly
elevated in vMC0-inoculated mice on day 5 postinoculation
Figure 3. Increased pulmonary expression of viral RNA sensors in response to inhalation of attenuated mengovirus. (A–C) Mice
received intranasal inoculations of 10
6 PFU of attenuated mengovirus, vMC0, an equivalent amount of UV-inactivated vMC0, or vehicle (n=6 mice per
group). (D–F) Mice were treated with anti-neutrophil mAb or control mAb before receiving intranasal inoculations of 10
6 PFU of vMC0 or vehicle
(n=5–6 mice per group). Levels of (A, D) TLR3, (B, E) TLR7, and (C, F) NOD2 mRNA in lungs on day 1 postinoculation were determined by real-time
quantitative RT-PCR and normalized to b-actin mRNA levels. * P,0.01 (vMC0 vs. vehicle or UV-inactivated vMC0), ** P,0.05 (anti-neutrophil mAb/
Vehicle vs. control mAb/Vehicle), { P=0.01 (anti-neutrophil mAb/vMC0 vs. control mAb/vMC0).
doi:10.1371/journal.pone.0032061.g003
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significant differences in numbers of eosinophils among the groups
(not shown). Giemsa-stained lung sections revealed patchy
peribronchial, perivascular, and alveolar cellular infiltrates in the
lungs of mice inoculated vMC0 but not in those inoculated with
vehicle or UV-inactivated vMC0 (Fig. 6).
The levels of lung-associated neutrophil-specific granule pro-
tein, myeloperoxidase (MPO), were significantly elevated on day 1
postinoculation in vMC0-inoculated, compared with vehicle-
inoculated, mice, indicating increased neutrophil recruitment to
the lung as a whole rather than just enhanced sequestration of
neutrophils into the airspace (Fig. 7A). MPO levels in the BAL
fluid, a marker of neutrophil activation, were also significantly
elevated on days 1, 2, 3, and 5 postinoculation in mice inoculated
with vMC0 compared with those inoculated with UV-inactivated
vMC0 or vehicle (Fig. 7B). CXCR2 and IL-17A mRNA levels
were significantly increased on day 1 postinoculation in the lungs
of mice inoculated with vMC0 compared with those inoculated
with vehicle or UV-inactivated vMC0 (Fig. 7C and D). CXCR2 is
the receptor on neutrophils for the neutrophil chemoattractant
chemokines, known as CXCR2 ligands, and therefore serves as a
useful marker for the presence of neutrophils [44]. IL-17A is an
important regulator of neutrophilic inflammation [45,46]. Along
with the vMC0-induced increase in BAL neutrophil levels, these
data demonstrate the development of neutrophilic airway
inflammatory responses in the lower airways of mice after
inhalation of infectious vMC0.
Expression of CXCR2 ligands in the lower airways after
inhalation of vMC0
Given the significant neutrophilia induced in the lower airways
by inhalation of vMC0, the expression of the mouse neutrophil
chemoattractant CXCR2 ligands, CXCL1, CXCL2, and
CXCL5, was measured. Levels of mRNA in the lung on day 1
postinoculation (Fig. 8A–C) and BAL fluid protein levels on day 2
postinoculation (Fig. 8D–F) for CXCL1, CXCL2, and CXCL5
were significantly elevated in mice inoculated with vMC0 in
comparison with those inoculated with vehicle or UV-inactivated
vMC0, demonstrating the availability of these chemokines to
mediate neutrophil recruitment.
Expression of CXCL10 and CCL2 in the lower airways after
inhalation of vMC0
Because HRV infection induces high levels of CXCL10 and
CCL2 expression [47–50], and CCL2 indirectly contributes to
neutrophil recruitment to the lungs [51], the expression of
CXCL10 and CCL2 was measured. Levels of CXCL10 and
CCL2 mRNA in the lungs on day 1 postinoculation and BAL fluid
levels of CCL2 on day 2 postinoculation were significantly
increased in vMC0-inoculated mice compared with vehicle- or
UV-inactivated vMC0-inoculated mice, indicating that the
picornavirus-induced expression of these chemokines in the lower
airways could be studied in this mouse model (Fig. 9).
Mucin expression in the lungs after inhalation of vMC0
HRV infection is associated with increased mucin expression
[52,53]. Therefore, mucin mRNA expression was measured.
MUC5B, but not MUC5AC, mRNA levels were significantly
elevated on day 1 postinoculation in the lungs of mice inoculated
with vMC0 as compared with vehicle-inoculated mice (Figure 10).
However, periodic acid-Schiff staining of lung sections from
vMC0-infected mice showed only sporadic staining for mucus-
producing cells in the airways (not shown).
Lung edema after inhalation of vMC0
To examine whether the lower airway inflammation induced by
vMC0 was associated with lung edema, wet:dry lung weight ratios
were measured. Wet:dry lung weight ratios were significantly
elevated on day 2 postinoculation in the lungs of mice inoculated
with vMC0 as compared with vehicle- and UV-vMC0-inoculated
mice, indicating the presence of acute lung injury (Fig. 11).
Effect of inhalation of vMC0 on pulmonary physiology
To examine whether infection of the lower airways with vMC0
induced changes in pulmonary physiology, mice received
intranasal inoculations of vMC0, UV-inactivated vMC0,o r
vehicle, and pulmonary function was measured on day 2
postinoculation. No significant differences were observed among
the groups with regard to respiratory system resistance (Rrs) or the
input impedance variables, Newtonian resistance (Rn), tissue
viscance (G), and elastance (H), either at baseline or in response to
methacholine challenge (Fig. 12 and data not shown), indicating a
lack of viral effects on pulmonary physiology and AHR.
Discussion
The establishment of useful and varied small animal models to
study HRV pathogenesis continues to be an important goal. Diverse
animal models can facilitate different types of mechanistic studies
and the development of potential new therapeutic strategies [54].
Recently, murine experimental models of HRV infection have been
established [23–28]. The development of these models represents a
significant advance in the study of HRV-induced airway inflamma-
tion. However, these models have an important limitation. Although
there is evidence of HRV replication in mice, HRV titers decline
quickly [23–26]. Therefore, the development of small animal models
with more robust viral replication could permit mechanistic studies
oftheroleviralreplicationplaysinHRVpathogenesis.Tomodelthe
role of viral replication in HRV-induced lower respiratory tract
Figure 4. Body weight reduction in response to inhalation of
attenuated mengovirus. Percent change in body weight on days 1
(n=26–30 mice per group), 2 (n=18–21 mice per group), 3 (n=14–16
mice per group), and 5 (n=9 mice per group) after intranasal
inoculation with 10
6 PFU of attenuated mengovirus, vMC0,a n
equivalent amount of UV-inactivated vMC0, or vehicle. Data are
presented as box plots. * P,0.001 (vMC0 vs. vehicle); ** P,0.0001,
*** P,0.01 (vMC0 vs. vehicle or UV-inactivated vMC0); { P,0.01 (vMC0
vs. UV-inactivated vMC0).
doi:10.1371/journal.pone.0032061.g004
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asthma in humans, it would be desirable to develop small animal
models where picornaviral replication occurs in the lower airways
and viral titers increase, peak, and then wane while persisting for
several days.
HRV is a picornavirus family member and viral replication is
often most efficient in the natural hosts of a virus. Therefore, we
have focused on developing small animal models using a
picornavirus, an attenuated form of mengovirus, whose natural
hosts are rodents. Previously, we described a rat model in which
the attenuated mengovirus, vMC0, caused a respiratory infection
in rats with several days of viral shedding accompanied by a
neutrophilic lower airway inflammatory response [36]. In the
mouse model described here, we observed an approximately 3 log
increase in vMC0 titers in the lungs from 0.1 h to 24 h
postinoculation, with viral shedding persisting for at least 5 days
after inoculation. The intranasal inoculum of 10
6 PFU of vMC0 in
the mice was similar to the dose of 5610
6 TCID50 administered
intranasally in HRV models in mice [23,24]. For comparison, we
inoculated mice with HRV-A01a, a minor group HRV, and found
that infectious viral titers in the lungs declined until they were
undetectable at 24 h postinoculation. Our HRV-A01 strain a
infection data were similar to previous reports in the literature with
a closely related minor receptor group virus, HRV-A01 strain b,
which showed a steep reduction in HRV titers over time in the
lungs of healthy, immunocompetent mice [23–26]. In one study,
after intranasal inoculation of 5610
6 TCID50 of HRV-A01b, viral
titers of approximately 10
3,1 0
3, and 10
2 TCID50/ml at 8, 16, and
24 h postinoculation, respectively, were reported [23]. In another
study [25], after intranasal inoculation with 5610
7 TCID50, a 10-
fold higher inoculum than used previously, lung viral titers were
approximately 10
2 and 10
1 TCID50/ml on days 1 and 4
postinoculation, although induction of substantial lung injury by
repeated treatment with lipopolysaccharide and elastase before
virus inoculation enhanced viral titers [25]. In a third study, lung
viral titers were somewhat higher after intranasal inoculation with
4.5610
6 TCID50 of HRV-A01b, with about 10
5 PFU/ml at 4 h
postinoculation steadily declining to about 10
1 PFU/ml on day 3
postinoculation before becoming undetectable at day 4 postino-
culation [26]. Overall, inhalation of HRV by mice led to some
degree of viral replication accompanied by a consistent pattern of
steadily declining levels of infectious virus in the lungs. In healthy,
immunocompetent mice, low levels of infectious HRV shedding
could be observed at 24 h postinoculation, and these levels
continued to fall until little or no infectious virus was detected by
day 4 postinoculation.
For both of our vMC0 and HRV-A01a inoculations, the
amount of infectious virus detected at 0.1 h postinoculation by
Figure 5. Recruitment of inflammatory cells to the lungs in response to inhalation of attenuated mengovirus. Numbers of (A) total
cells, (B) neutrophils, (C) lymphocytes, and (D) macrophages in the BAL fluid harvested at the indicated times from the lungs of mice inoculated with
10
6 PFU of vMC0, an equivalent amount of UV-inactivated vMC0, or vehicle (n=6 mice per group). Data are presented as box plots. { P,0.05,
* P,0.01, ** P,0.001, *** P,0.0001 (vMC0 vs. vehicle or UV-inactivated vMC0).
doi:10.1371/journal.pone.0032061.g005
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discrepancy was probably due to deposition of some of the virus in
the nasopharynx and gastrointestinal tract as well as the eclipsing
of the virus in the lung during the early stage of the infection.
Importantly, the starting levels of virus in the lungs were similar for
vMC0 and HRV-A01a, but the viral replication and persistence
were greater with vMC0.
.Along with the evidence of notable levels of viral replication
and persistent viral shedding in the lower respiratory tract, this
mouse model has many features in common with HRV infection
in humans. Inhalation of live, but not inactivated vMC0, induced
signs of illness such as significant body weight loss, which is a
hallmark of viral respiratory illnesses in rodents. Infection of the
lower respiratory tract with vMC0 resulted in the stimulation of
host antiviral pathways much in the same way as HRV. There was
a marked increase in Type I and III IFN proteins in the airway
fluids as early as 1 day after virus inoculation, which also provides
further evidence of viral replication in the lungs after vMC0
infection. Regulation of type I and III IFN production has been
implicated as an important checkpoint in the host response to
HRV infection [37–39]. In addition, pulmonary expression of the
viral RNA sensors, TLR3, TLR7, and NOD2 were upregulated
by vMC0 infection. The viral RNA sensors, TLR3 and TLR7,
have been implicated in the host response to HRV infections
[26,40,41]. NOD2 is an intriguing pattern recognition receptor
because it not only detects bacterial peptidoglycan but can also
function as a viral RNA sensor [42]. NOD2 has not been
previously implicated in host responses to HRV. However, given
its upregulation in the lungs in response to vMC0 infection, it will
be of interest to examine its role in HRV infection. Depletion of
neutrophils before the virus inoculation did not inhibit the
subsequent upregulation of these viral RNA sensors, which was
consistent with a vMC0-associated increase in expression in
resident lung cells. In all cases, stimulation of these host antiviral
pathways required active vMC0.
Recruitment of neutrophils and lymphocytes to the airways are
common features of vMC0- and HRV-induced airway infections,
and the chemokine milieu that was observed in the lung tissue and
airway fluids in the vMC0-infected mice has marked similarities to
that observed in HRV infections in humans. Increased pulmonary
expression of the neutrophil chemoattractant CXCR2 ligands in
response to vMC0 infection is consistent with the increased
expression of CXCR2 ligands that is observed in response to HRV
infection in humans and in mouse models [23,24,55–58]. We also
observed the induction of pulmonary expression of CXCL10 and
CCL2 in response to inhalation of vMC0, showing another
similarity between this mouse model of picornaviral airway
infection and HRV infection. CXCL10 and CCL2 expression
have been shown to be markedly upregulated in response to HRV
infection [23,24,47–50,59].
There was also evidence of acute airway injury, as shown by the
development of lung edema, which might be related to the
neutrophilic airway inflammation observed in the lower respira-
tory tract and the evidence for neutrophil activation, i.e., the
release of the neutrophil granule protein MPO in the airway fluids.
In addition the vMC0 infection stimulated increased pulmonary
expression of MUC5B mRNA. It is not clear why MUC5AC
mRNA expression was not increased as well. In humans, HRV
infection has been shown to stimulate mucin expression [52,53].
Although we only observed sporadic staining for mucus-producing
cells in the airways, it is possible that mucin gene expression
induced by vMC0 infection might have greater biological
relevance in the exacerbation of existing airway disease in mice.
Similar to what we reported in our rat model of vMC0-induced
airway infection and inflammation [36], inhalation of vMC0 by
mice had no significant effect on baseline pulmonary function or
AHR to methacholine challenge. As in our previous rat study,
experimentally naı ¨ve adult animals without existing airway disease
were used in these mouse studies. Similar to our rodent models,
almost all reports of experimental HRV inoculations of healthy,
nonasthmatic, nonallergic human subjects have resulted in no
significant postinoculation changes in baseline pulmonary function
or AHR [11,60–64]. One study showed small differences in AHR
after experimental HRV infection of nonasthmatic, nonallergic
subjects, but these small changes were only detectable at a
methacholine concentration that was a half-log above the upper
end of the typical dose range [65]. However, experimental HRV
inoculation was shown to increase AHR in some individuals with
asthma and/or allergic rhinitis in several studies [11,22,64,66,67]
but not in others [60,61,63,65,68]. Consequently, the lack of AHR
changes in healthy adult mice without existing airway disease was
consistent with outcomes of experimental HRV infections in
Figure 6. Recruitment of inflammatory cell infiltrates to the
lungs in response to inhalation of attenuated mengovirus.
Giemsa-stained sections of the lungs from mice intransasally inoculated
with (A) vehicle, (B) vMC0 (10
6 PFU) or (C) an equivalent amount of UV-
inactivated vMC0. Lungs were harvested on day 2 postinoculation.
Magnification, 20X.
doi:10.1371/journal.pone.0032061.g006
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allergic rhinitis. Overall, the absence of pulmonary function
changes during vMC0-induced lower respiratory infection in mice
without existing airway disease is consistent with observations in
experimental HRV infections in healthy human volunteers. The
absence of viral effects on AHR is also consistent with one mouse
model of HRV infection in which no increase in AHR to
methacholine challenge was observed after HRV infection unless
the BALB/c mice had underlying experimental allergic airway
inflammation [23]. However, in another model, a modest increase
in AHR to methacholine challenge was reported after infection of
C57BL/6 mice with HRV [24], which might be related to mouse
strain differences. The underlying condition of the airways,
whether related to genetic, developmental, and/or environmental
factors, may have profound effects on host responses to
picornaviral airway infection and the outcomes of these infections.
In the future, it will be of interest to investigate the influence of
age, genetic factors, and other environmental exposures, such as
allergens, other respiratory viruses [69], or microbial factors, on
host responses to vMC0-induced lower respiratory tract infection.
A potential limitation of using vMC0 in this mouse model of
respiratory infection is that, unlike HRV, mengovirus is neuro-
tropic. However, it is important to note that the HRV, as
enteroviruses, are closely related to poliovirus, which is also
neurotropic. Inhalation of the attenuated mutant of mengovirus,
vMC0, induced a self-limited respiratory infection in rodents,
demonstrating the plasticity of vMC0 with regard to its tissue
tropism. After intranasal inoculation with vMC0, there was no
evidence of systemic infection in homogenates of nonrespiratory
organs, as tested by plaque assay (not shown), which was consistent
with our previous work in rats [36]. We chose to use plaque assays
for the detection of virus because our primary interest was in
measuring titers of infectious virus. We cannot rule out the
possibility that vMC0 RNA might have been detected in
nonrespiratory organs if a highly sensitive PCR-based assay had
been used. In fact, HRV viremia has been detected in some
human patients by highly sensitive PCR-based assays [70,71].
The picornaviral airway infection models in rodents involve a
single viral inoculation, which is comparable to experimental
HRV inoculation studies in human subjects. An HRV infection
Figure 7. Neutrophilic inflammation in the lungs in response to inhalation of attenuated mengovirus. Mice received intranasal
inoculations of 10
6 PFU of attenuated mengovirus, vMC0, an equivalent amount of UV-inactivated vMC0, or vehicle. (A) Lung-associated MPO levels
on day 1 postinoculation. MPO levels in lung tissue homogenates from mice inoculated with vehicle or vMC0 were determined by ELISA and
normalized to total protein levels (n=4 mice per group). (B) MPO release into airway fluids. BAL fluid was harvested on the indicated days, and MPO
levels were determined by ELISA (n=6 mice per group). Data are the total amount of MPO recovered (ELISA values were multiplied by the BAL fluid
volume). MPO levels below the limit of detection were assigned a value of 1 ng for graphing purposes. (C) CXCR2 and (D) IL-17A expression in the
lungs on day 1 postinoculation. Levels of CXCR2 and IL-17A mRNA were determined by real-time quantitative RT-PCR and normalized to b-actin
mRNA levels (n=6 mice per group). Data are presented as box plots. * P,0.05 (vMC0 vs. vehicle). ** P,0.01 (vMC0 vs. vehicle or UV-inactivated vMC0).
doi:10.1371/journal.pone.0032061.g007
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and adults [1], and experiencing an HRV wheezing illness early in
life is associated with an increased risk for the subsequent
development of childhood asthma [2–4]. Thus, these rodent
models should be useful for relevant mechanistic studies. Some
children appear to exhibit increased susceptibility to recurrent
HRV infections, presumably caused by exposure to differing
serotypes [72,73], but the precise role of recurrent HRV infections
Figure 8. Increased pulmonary expression of CXCR2 ligands in response to inhalation of attenuated mengovirus. Mice received
intranasal inoculations of 10
6 PFU of attenuated mengovirus, vMC0, an equivalent amount of UV-inactivated vMC0, or vehicle (n=6 mice per group).
Levels of (A) CXCL1 (KC), (B) CXCL2 (MIP-2), and (C) CXCL5 (LIX) mRNA in lungs on day 1 postinoculation were determined by real-time quantitative
RT-PCR and normalized to b-actin mRNA levels. Levels of (D) CXCL1, (E) CXCL2, and (F) CXCL5 protein in BAL fluid on day 2 postinoculation were
determined by ELISA. Data are the total amount of chemokine recovered (ELISA values were multiplied by the BAL fluid volume). CXCL2 protein levels
below the limit of detection (dotted line) were assigned a value of 4 pg for graphing purposes. Data are presented as box plots. * P#0.01, ** P,0.05
(vMC0 vs. vehicle or UV-inactivated vMC0).
doi:10.1371/journal.pone.0032061.g008
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picornaviral airway infections would be more challenging to study
in animal models because of the limited serotypic diversity of
viruses that have been experimentally tested in mice, but one
possibility would involve sequential inoculation of vMC0 and
HRV because there should be limited immune crossreactivity
between these picornaviruses.
A comparison between our mengovirus infection model and the
HRV infection model in mice [23–28] shows that they both
induce a neutrophilic inflammatory response in the lower
respiratory tract, which is consistent with the inflammatory
responses induced by HRV infections in humans. By mimicking
important aspects of natural HRV infections in humans, both
models should facilitate mechanistic studies that would be difficult
to perform in human subjects. The HRV infection model in mice
allows for the effects of the actual human virus to be studied
directly, but HRV is not a natural mouse pathogen and does not
replicate efficiently in mice. An important distinction is that
mengovirus, a natural mouse pathogen, replicates more efficiently
in mice than does HRV. Our data show that after inhalation of
vMC0, viral titers in the lung increase, peak, and then wane while
persisting for at least 5 days. Overall, both of these models have
strengths and limitations, and the relative usefulness of each model
will depend on the specific research questions that are being
addressed.
In conclusion, we have developed of a robust model of
picornavirus-induced airway infection and inflammation in mice.
One of this model’s key strengths is that it employs a natural
pathogen for rodents, mengovirus, which yields viral replication
kinetics and magnitudes closer to natural viral respiratory
infections. HRV infection models in mice are proving to be useful
for the study of HRV-induced airway inflammation but have a
weaker component of viral replication. The mengovirus airway
infection model should complement these existing models, and
should be especially useful for studies where viral replication is an
important outcome.
Materials and Methods
Ethics statement
The mice were housed and all experimental procedures were
performed in an American Association for Accreditation of
Laboratory Animal Care-accredited laboratory animal facility at
the University of Wisconsin School of Medicine and Public
Health. The study was approved by the University of Wisconsin
School of Medicine and Public Health Animal Care and Use
Committee (protocol number M00582) and conformed to the
Guide for the Care and Use of Laboratory Animals.
Animals
Female BALB/cAnNCr mice were purchased from the
National Cancer Institute Animal Production Program (Frederick,
MD) and used at 6–10 weeks of age for inoculation studies. The
mice were housed in microisolator cages within HEPA-filtered
isolation cubicles (Britz & Company, Wheatland, WY).
Virus
Recombinant vMC0 has been described previously [31]. To
prepare stocks of vMC0, the plasmid containing the entire vMC0
cDNA was linearized and transcribed in vitro with T7 RNA
polymerase. The viral RNA was transfected into HeLa cells, and
plaques were isolated and eluted overnight. The viral plaque
eluate was used to inoculate fresh plates of HeLa cells which were
incubated for 24 h at 37uC. The plates were then frozen, thawed,
Figure 9. Increased pulmonary expression of CXCL10 and CCL2
in response to inhalation of attenuated mengovirus. Mice
received intranasal inoculations of 10
6 PFU of attenuated mengovirus,
vMC0, an equivalent amount of UV-inactivated vMC0, or vehicle (n=6
mice per group). Levels of (A) CXCL10 (IP-10) and (B) CCL2 (MCP-1)
mRNA in lungs on day 1 postinoculation were determined by real-time
quantitative RT-PCR and normalized to b-actin mRNA levels. (C) CCL2
protein levels in BAL fluid on day 2 postinoculation were determined by
ELISA. Data are the total amount of CCL2 recovered (ELISA values were
multiplied by the BAL fluid volume). ND, not detectable. Data are
presented as box plots. * P,0.01 (vMC0 vs. vehicle or UV-inactivated
vMC0).
doi:10.1371/journal.pone.0032061.g009
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cycles before centrifugation to remove cellular debris. This lysate
was used to inoculate HeLa cells (multiplicity of infection=1)
grown in suspension to a density of 4610
8 cells/ml. Flasks were
incubated at 37uC for 9 h in a shaking water bath and then frozen
at 280uC. Viral stocks were concentrated and purified by
centrifugation through a 30% sucrose cushion. Titers were
determined by duplicate plating on HeLa cell monolayers [74].
UV-inactivated vMC0 stocks were prepared by exposing the virus
to a germicidal UV lamp for 30 min. Plaque assays using HeLa
cells were employed to verify that active virus was undetectable
[,10 PFU/ml] in the UV-inactivated preparations. Purified
HRV-A, genotype 1 (A01a) was provided by Dr. Wai-Ming Lee
(University of Wisconsin-Madison, Madison, WI).
Virus inoculation and measurement of viral titers
Mice were inoculated intranasally with vehicle, 10
6 PFU of
vMC0,1 0
6 PFU equivalents of UV-inactivated vMC0,o r5 610
6
PFU of HRV-A01a under isoflurane anesthesia. For virus
titration, lungs were removed from the chest cavity aseptically
and weighed. The lungs were homogenized with an automated
tissue homogenizer in an appropriate volume of phosphate-
buffered saline (PBS) to yield a 10% w/v homogenate. Cell debris
were removed by centrifugation, and the supernates were titered
for virus by duplicate plating on HeLa cell monolayers [74].
Depletion of neutrophils
Purified anti-neutrophil mAb 1A8 (mouse Gr-1/Ly-6G-specific)
and isotype-matched control mAb 2A3 (rat IgG2a; ,0.18 and
,0.63 endotoxin units/mg by Limulus amebocyte lysate test,
respectively) were purchased from Bio X Cell (West Lebanon,
NH). Anti-neutrophil mAb was administered to each mouse by
both intraperitoneal and intranasal routes, which has been
Figure 10. Mucin expression in the lungs in response to inhalation of attenuated mengovirus. Mice received intranasal inoculations of
10
6 PFU of attenuated mengovirus, vMC0, or vehicle (n=5 mice per group). Levels of (A) MUC5B and (B) MUC5AC mRNA in lungs on day 1
postinoculation were determined by real-time quantitative RT-PCR and normalized to b-actin mRNA levels. * P,0.01 (vMC0 vs. vehicle).
doi:10.1371/journal.pone.0032061.g010
Figure 11. Lung edema in response to inhalation of attenuated
mengovirus. Wet:dry lung weight ratios were measured for lungs
harvested on day 2 after intranasal inoculation with 10
6 PFU of
attenuated mengovirus, vMC0, an equivalent amount of UV-inactivated
vMC0, or vehicle (n=9 mice per group). Data are presented as box plots;
whiskers indicate the 10th and 90th percentiles. * P,0.01 (vMC0 vs.
vehicle or UV-inactivated vMC0).
doi:10.1371/journal.pone.0032061.g011
Figure 12. Effect of inhalation of attenuated mengovirus on
pulmonary physiology. Mice received intranasal inoculations of
vehicle, 10
6 PFU of attenuated mengovirus, vMC0 (n=6–7 mice per
group), or an equivalent amount of UV-inactivated vMC0 (n=4 mice),
and on day 2 postinoculation, pulmonary physiology measurements
were obtained after exposure to aerosols of normal saline followed by
escalating concentrations of methacholine. Values for respiratory
system resistance (Rrs) are presented as the group means 6 the
standard error. There were no significant differences among the groups.
doi:10.1371/journal.pone.0032061.g012
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respiratory tract [75]. However, we used mAb 1A8 to deplete
neutrophils rather than mAb RB6-8C5 because of its greater
selectivity for neutrophils [76]. 1A8 was effective in depleting
neutrophils, as a single intraperitoneal injection of 1A8 (500 mg)
the day before virus inoculation reduced the day 1 postinoculation
vMC0-induced increase in lung MPO protein levels by 81% in
comparison with mice receiving 2A3 (500 mg) (n=4 mice per
group). One day before intranasal inoculation with either vehicle
or 10
6 PFU of vMC0, mice received intraperitoneal injections of
500 mg and intranasal instillations (under isoflurane anesthesia) of
200 mg of either 1A8 or 2A3 in PBS. On the day of inoculation,
the mice received an additional intraperitoneal injection of 500 mg
of either 1A8 or 2A3 in PBS.
Measurements of pulmonary inflammation
Mice were anesthetized and exsanguinated by severing the
dorsal aorta. After opening the chest, BAL was performed. The
lungs were lavaged with 800 ml of PBS via a tracheal catheter.
The lungs were then lavaged again in the same manner, and the
BAL fluid samples were combined. The BAL fluid was
centrifuged, and the cell pellet was resuspended in 0.2 ml of
PBS. The total number of BAL leukocytes was determined with an
automated cell counter (model Z1, Beckman Coulter, Hialeah,
FL). Differential cell counts were determined by counting 200
leukocytes on cytospin slides stained with ProtocolH Wright-
Giemsa stain according to the manufacturer’s protocol (Fisher
Diagnostics, Middletown, VA). BAL fluid was stored at 280uC.
For histological assessments of pulmonary inflammation, mouse
lungs were filled with 10% formalin, tied off, removed from the
chest cavity, and immersed in 10% formalin for 24 h. The tissue
was then processed, embedded in paraffin, and cut into 5 mm
sections. Sections were stained with a Giemsa stain.
Measurements of pulmonary protein expression
The levels of specific proteins in the BAL fluid or lung
homogenates were measured by enzyme-linked immunosorbent
assay (ELISA). Mouse CXCL1 (KC, keratinocyte-derived cyto-
kine)-specific, CXCL2 (MIP-2, macrophage inflammatory protein-
2)-specific, and IFN-b-specific ELISA kits with sensitivities of
7.8 pg/ml and Mouse IFN-a-specific kits with a sensitivity of
12.5 pg/ml were purchased from Invitrogen (Carlsbad, CA).
Mouse CXCL5 (LIX, lipopolysaccharide-induced CXC chemo-
kine)-specific and IFN-l-specific ELISA kits with sensitivities of
7.8 pg/ml were acquired from R&D Systems (Minneapolis, MN).
Mouse CCL2 (MCP-1, monocyte chemoattractant protein-1)-
specific ELISA kits with a sensitivity of 7.8 pg/ml were purchased
from BD Biosciences (San Diego, CA). Mouse MPO-specific
ELISA kits with a sensitivity of 0.4 ng/ml were obtained from Cell
Sciences Incorporated (Canton, MA). Total protein levels in lung
homogenates were measured by the Coomassie Plus (Bradford)
Protein Assay (Pierce, Rockford, IL).
Measurements of pulmonary gene expression
For RNA isolation, mouse lungs were harvested in an RNase-
free manner and immediately flash-frozen in liquid nitrogen.
Lungs were then powdered under liquid nitrogen with a chilled
mortar and pestle. Total RNA was isolated from frozen lung
powder with an RNeasy Mini Kit according to the manufacturer’s
instructions (Qiagen, Valencia, CA). The total RNA was reverse
transcribed into cDNA with SuperScriptH III reverse transcriptase
following the manufacturer’s instructions (Invitrogen, Carlsbad,
CA). The cDNA product was diluted 1:2.5 fold and used as the
template for quantitative real-time PCR, which was performed
using an ABI 7500 Real Time PCR System (Applied Biosystems,
Foster City, CA). TaqManH primer and probe sets for TLR3,
TLR7, NOD2, CXCL1, CXCL2, CXCL5, CXCL10 (IP-10,
IFN-gamma inducible protein 10), CCL2, MUC5B, MUC5AC,
and b-actin were purchased from Applied Biosystems. All values
were normalized to the endogenous control, b-actin. Standard
curves were generated by serial dilutions of cDNA from the lungs
of a vMC0-inoculated mouse and used to determine relative
expression levels.
Measurement of lung edema
To measure lung edema, wet:dry lung weight ratios were
determined. Lungs were removed from the chest cavity and
immediately weighed to obtain the wet lung weight. All lungs were
place in an oven at 65uC for 4 days and then weighed again to
determine the dry lung weight.
Measurements of pulmonary physiology
Mice were anesthetized with pentobarbital (Abbott, North
Chicago, IL), intubated via tracheostomy, paralyzed with
succinylcholine HCl (Sigma, St. Louis, MO), and ventilated
mechanically (flexiVent, SCIREQ, Montreal, QC, Canada).
Aerosol challenges were delivered by the ventilator via an inline
nebulizer (Aeroneb, SCIREQ) with aerosolized normal saline
being followed by methacholine HCl (Sigma) solutions in
concentrations of 1, 3, 10, and 30 mg/ml. After each aerosol
challenge, measurements of pulmonary physiology were per-
formed by the flexiVent system, alternating measures of Rrs with
measures of input impedance variables (Rn, G, and H). For each
variable, the highest value occurring after each aerosol challenge
was recorded as the response, referenced to the value obtained
after saline challenge.
Statistical analysis
The numbers of total cells, neutrophils, lymphocytes, and
macrophages in the BAL fluid were analyzed by an analysis of
variance (general linear model), which was followed by planned
pairwise comparisons using Fischer’s least significant difference
test. A residual analysis was employed to test the adequacy of the
models. Pulmonary physiology data were analyzed by an analysis
of covariance, using the values from the methacholine dose
30 mg/ml as the dependent variable and baseline (after saline)
values as the covariate to account for differences in baselines.
Nonparametric tests were used to analyze all other data. The
Kruskal-Wallis test was used for comparisons among three or
more groups and was followed by planned pairwise comparisons
using the Mann-Whitney test. For comparisons between two
groups, the Mann-Whitney test was used. Box plots depict the
median and the interquartile range between the 25th and 75th
percentile, and whiskers show the 10th and 90th percentiles.
Analyses were performed using the statistical software package
SYSTAT 11.0 (Systat Software, Chicago, IL).
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